COMP <GO>
REPL vs MAZE // EV/EBITDA & P/E VALUATION
Replimune Group Inc. (NASDAQ) VS. Maze Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: REPL 2
— MAZE 2
■ METRIC PARITY
LAST: $17.39 (+8.28%) • MKT CAP: $1.65B
valuation
—
LAST: $31.93 (+0.63%) • MKT CAP: $1.77B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REPL VS. MAZE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REPL | MAZE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.01% | -6.36% | -10.65 | MAZE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | REPL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.1 | 63.3 | +11.86 | REPL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.65B | $1.77B | -$125.1M | MAZE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REPL REV | MAZE REV | REPL GROSS % | MAZE GROSS % | REPL FCF | MAZE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$280.3M | -$112.7M |
| FY 2024 | $0 | $167.5M | — | — | -$192.3M | $74.8M |
| FY 2023 | $0 | — | — | — | -$185.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REPL // BETA —
MAZE // BETA —